Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabapentin SCHEMBL179836 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL8343 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL4030100 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL466183 | 1.00 | CYP1A2 (1.00) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL6672099 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL6689206 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL19031792 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL7340062 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL26730 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Gabapentin SCHEMBL1828034 | 0.98 | CYP1A2 (0.96) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SOLCHEM ITALIANA S.P.A. (IT) | 2004-04-01 | — | — | US | claimed |
| EP-1373186-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | Solchem Italiana S.p.A (IT) | 2004-01-02 | — | — | EP | claimed |
| WO-2002074727-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | SOLCHEM ITALIANA S.P.A. (IT) | 2002-09-26 | — | — | WO | claimed |
| EP-1820794-B1 | METHOD OF OBTAINING CYCLIC AMINO ACIDS | MENADIONA SL (ES) | 2011-01-05 | — | — | EP | disclosed |
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SOLCHEM ITALIANA S.P.A. (IT) | 2004-04-01 | — | — | US | disclosed |
| EP-1373186-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | Solchem Italiana S.p.A (IT) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074727-A1 | A PROCESS FOR THE PREPARATION OF CYCLIC AMINO ACIDS | SOLCHEM ITALIANA S.P.A. (IT) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063994-A1 | Process for the preparation of cyclic amino acids | SLC7A1, MRPL21, BCAT1 | CYP1A2 2422/4885ALDH1A1 2987/4885USP2 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.